The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells

Maha S Al-Keilani,1 Karem H Alzoubi,1 Saied A Jaradat2,3 1Department of Clinical Pharmacy, College of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan; 2Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid 22110, Jordan; 3P...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Al-Keilani MS, Alzoubi KH, Jaradat SA
Format: article
Langue:EN
Publié: Dove Medical Press 2018
Sujets:
Accès en ligne:https://doaj.org/article/6d17358580134186b50e93e8fd057d06
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!